A randomised controlled trial studied the effect of the neurokin-1 receptor antagonist orvepitant on cough frequency and found a meaningful reduction in high frequency coughers .
Refractory or unexplained chronic cough is an incapacitating and widespread disease with negative influence on quality of life that is often challenging to treat . Currently, there are no proven therapies for this condition, which is often treated off-label with first-generation antihistamines, antidepressants, and opioids – with mixed results. The phase 2b, multicentre, double-blind, randomised controlled VOLCANO-2 trial involved 315 patients from 55 sites all over North America and the United Kingdom . Every study subject had chronic or unexplained chronic cough. Prerequisite for study inclusion was ≥1 year of cough of unclear origin and/or no treatment response, with an awake frequency of ≥10 coughs per hour .
The orvepitant group received either 10 mg, 20 mg...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Balloon Pulmonary Angioplasty for Inoperable Chronic Thromboembolic Pulmonary Hypertension Next Article
Female COPD Patients Frequently Suffer from Anxiety and Depression »
Table of Contents: ERS 2019
Holistic View on Asthma
Infectious Respiratory Disease: the Role of Vaccines
Interstitial Lung Disease
Best of the Posters
Novel Developments in Infectious Disease
A New Trial in Pulmonary Vascular Disease
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.